UroGen Pharma Ltd.
URGN
$47.11
$0.801.73%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 72.46M | 50.96M | 37.84M | 27.48M | 24.22M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 72.46M | 50.96M | 37.84M | 27.48M | 24.22M |
| Cost of Revenue | 6.57M | 4.14M | 3.29M | 3.28M | 3.55M |
| Gross Profit | 65.88M | 46.82M | 34.55M | 24.20M | 20.67M |
| SG&A Expenses | 48.44M | 51.49M | 39.35M | 37.58M | 43.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 72.35M | 71.22M | 56.95M | 54.87M | 65.66M |
| Operating Income | 111.00K | -20.26M | -19.12M | -27.39M | -41.45M |
| Income Before Tax | -8.72M | -28.35M | -26.64M | -34.40M | -48.93M |
| Income Tax Expenses | 5.63M | -4.77M | -275.00K | -1.05M | 1.02M |
| Earnings from Continuing Operations | -14.35M | -23.57M | -26.36M | -33.35M | -49.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14.35M | -23.57M | -26.36M | -33.35M | -49.94M |
| EBIT | 111.00K | -20.26M | -19.12M | -27.39M | -41.45M |
| EBITDA | 189.00K | -20.19M | -19.04M | -27.31M | -41.37M |
| EPS Basic | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 |
| Normalized Basic EPS | -0.11 | -0.35 | -0.34 | -0.45 | -0.64 |
| EPS Diluted | -0.28 | -0.47 | -0.54 | -0.69 | -1.05 |
| Normalized Diluted EPS | -0.11 | -0.35 | -0.34 | -0.45 | -0.64 |
| Average Basic Shares Outstanding | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M |
| Average Diluted Shares Outstanding | 50.38M | 50.18M | 49.23M | 48.06M | 47.74M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |